一分钟看懂
这是一项关于Familial Chylomicronemia Syndrome (FCS)的早期 I 期研究，登记的药物或干预包括CS-121，当前状态为招募中。登记地点显示中国合肥有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
CS-121 · 早期 I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Affiliated Hospital of Anhui Medical University · 合肥
公开的入选条件
- * Male or female aged 18 to 55 years (inclusive) at the time of signing informed consent.
- * On regular standard therapy with good compliance, but fasting triglyceride (TG) levels have not been consistently reduced below 10 mmol/L (880 mg/dL); i.e., before screening, there must be records of at least three separate fasting TG values \>10 mmol/L (880
- * North American Familial Chylomicronemia Syndrome (NAFCS) score ≥45
- * Able to sign informed consent and comply with the requirements and restrictions specified in the informed consent form and the protocol, such as dietary guidance and intake restrictions.
- * Female participants must meet one of the following: be not of childbearing potential (e.g., documented hysterectomy, bilateral salpingectomy/sterilization, or ≥1 year postmenopausal); or, if of childbearing potential, have a negative pregnancy test at screen
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07176923；登记信息更新于 2026-02-11。